208 related articles for article (PubMed ID: 33277443)
21. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Shi XN; Li H; Yao H; Liu X; Li L; Leung KS; Kung HF; Lu D; Wong MH; Lin MC
PLoS One; 2015; 10(7):e0132072. PubMed ID: 26147897
[TBL] [Abstract][Full Text] [Related]
22. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
[TBL] [Abstract][Full Text] [Related]
23. A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-Cdk2 during cell cycle progression.
Sørensen CS; Lukas C; Kramer ER; Peters JM; Bartek J; Lukas J
Mol Cell Biol; 2001 Jun; 21(11):3692-703. PubMed ID: 11340163
[TBL] [Abstract][Full Text] [Related]
24. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
25. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
[TBL] [Abstract][Full Text] [Related]
26. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.
Linzen U; Lilischkis R; Pandithage R; Schilling B; Ullius A; Lüscher-Firzlaff J; Kremmer E; Lüscher B; Vervoorts J
PLoS One; 2015; 10(4):e0123736. PubMed ID: 25860957
[TBL] [Abstract][Full Text] [Related]
27. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Duong MT; Akli S; Wei C; Wingate HF; Liu W; Lu Y; Yi M; Mills GB; Hunt KK; Keyomarsi K
PLoS Genet; 2012; 8(3):e1002538. PubMed ID: 22479189
[TBL] [Abstract][Full Text] [Related]
28. UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.
Abe S; Kubota T; Otani Y; Furukawa T; Watanabe M; Kumai K; Akiyama T; Akinaga S; Kitajima M
Jpn J Cancer Res; 2001 May; 92(5):537-45. PubMed ID: 11376563
[TBL] [Abstract][Full Text] [Related]
29. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
30. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
31. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex.
Zhang G; Ma F; Li L; Li J; Li P; Zeng S; Sun H; Li E
Biochem Pharmacol; 2019 May; 163():133-141. PubMed ID: 30772267
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence.
Bazzar W; Bocci M; Hejll E; Högqvist Tabor V; Hydbring P; Grandien A; Alzrigat M; Larsson LG
Cell Cycle; 2021 Jan; 20(1):23-38. PubMed ID: 33356836
[TBL] [Abstract][Full Text] [Related]
34. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes.
Mitra J; Enders GH; Azizkhan-Clifford J; Lengel KL
Cell Cycle; 2006 Mar; 5(6):661-6. PubMed ID: 16582612
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation.
Hydbring P; Bahram F; Su Y; Tronnersjö S; Högstrand K; von der Lehr N; Sharifi HR; Lilischkis R; Hein N; Wu S; Vervoorts J; Henriksson M; Grandien A; Lüscher B; Larsson LG
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):58-63. PubMed ID: 19966300
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Rao SS; Stoehr J; Dokic D; Wan L; Decker JT; Konopka K; Thomas AL; Wu J; Kaklamani VG; Shea LD; Jeruss JS
Oncotarget; 2017 Oct; 8(48):83925-83939. PubMed ID: 29137393
[TBL] [Abstract][Full Text] [Related]
38. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
[TBL] [Abstract][Full Text] [Related]
39. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity.
Takahashi T; Yamasaki F; Sudo T; Itamochi H; Adachi S; Tamamori-Adachi M; Ueno NT
Mol Cancer Ther; 2005 Jul; 4(7):1039-46. PubMed ID: 16020661
[TBL] [Abstract][Full Text] [Related]
40. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
